CN104395286A - A kind of preparation method of lactam compound - Google Patents
A kind of preparation method of lactam compound Download PDFInfo
- Publication number
- CN104395286A CN104395286A CN201380033724.XA CN201380033724A CN104395286A CN 104395286 A CN104395286 A CN 104395286A CN 201380033724 A CN201380033724 A CN 201380033724A CN 104395286 A CN104395286 A CN 104395286A
- Authority
- CN
- China
- Prior art keywords
- solvent
- combination
- formula
- halide
- compound shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 lactam compound Chemical class 0.000 title claims description 55
- 238000002360 preparation method Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 13
- 239000003054 catalyst Substances 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- 150000002828 nitro derivatives Chemical class 0.000 claims description 46
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- GUGXRXLTTHFKHC-UHFFFAOYSA-N 4-(2-methylpropyl)pyrrolidin-2-one Chemical compound CC(C)CC1CNC(=O)C1 GUGXRXLTTHFKHC-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000012279 sodium borohydride Substances 0.000 claims description 15
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 15
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 12
- 239000011591 potassium Substances 0.000 claims description 12
- 229910052700 potassium Inorganic materials 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 229910001507 metal halide Inorganic materials 0.000 claims description 11
- 150000005309 metal halides Chemical class 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052759 nickel Inorganic materials 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical group COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- 239000004280 Sodium formate Substances 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 2
- YPTUAQWMBNZZRN-UHFFFAOYSA-N dimethylaminoboron Chemical compound [B]N(C)C YPTUAQWMBNZZRN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 2
- 229910052987 metal hydride Inorganic materials 0.000 claims description 2
- 150000004681 metal hydrides Chemical class 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 235000007686 potassium Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019254 sodium formate Nutrition 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000006197 hydroboration reaction Methods 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract description 7
- 229960001233 pregabalin Drugs 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 0 CC(C)CC(C*)C[N+]([O-])=O Chemical compound CC(C)CC(C*)C[N+]([O-])=O 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical group I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical group O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical group [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical group Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- IPLJNQFXJUCRNH-UHFFFAOYSA-L nickel(2+);dibromide Chemical compound [Ni+2].[Br-].[Br-] IPLJNQFXJUCRNH-UHFFFAOYSA-L 0.000 description 1
- UQPSGBZICXWIAG-UHFFFAOYSA-L nickel(2+);dibromide;trihydrate Chemical compound O.O.O.Br[Ni]Br UQPSGBZICXWIAG-UHFFFAOYSA-L 0.000 description 1
- UGNANEGDDBXEAS-UHFFFAOYSA-L nickel(2+);dichloride;dihydrate Chemical compound O.O.Cl[Ni]Cl UGNANEGDDBXEAS-UHFFFAOYSA-L 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical group Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及制备普瑞巴林及其中间体内酰胺化合物的方法。The invention relates to a method for preparing pregabalin and its intermediate lactam compound.
背景技术Background technique
普瑞巴林(Pregabalin)具有镇痛,抗惊厥和抗焦虑活性,对癫痫发作有预防作用。Pregabalin has analgesic, anticonvulsant and anxiolytic activity, and has a preventive effect on epileptic seizures.
内酰胺化合物4-异丁基-2-吡咯烷酮(02)为合成普瑞巴林的一个关键中间体,简便地得到合格的4-异丁基-2-吡咯烷酮(02)对普瑞巴林的合成有重要意义。The lactam compound 4-isobutyl-2-pyrrolidone (02) is a key intermediate for the synthesis of pregabalin, and the qualified 4-isobutyl-2-pyrrolidone (02) is easily obtained for the synthesis of pregabalin. Significance.
现有技术中有多种方法制备4-异丁基-2-吡咯烷酮。例如,专利申请CN200910266661.8或WO2006110783中公开了制备4-异丁基-2-吡咯烷酮的相关方法;但这些方法需要用到氢气和/或高压设备或者以其它底物经过多步骤才能得到,反应时间长,工艺繁琐和/或存在较大不安全因素。因此需要一种对设备要求低,安全,操作工艺简便而收率高的方法,以适于工业化生产。There are various methods for preparing 4-isobutyl-2-pyrrolidone in the prior art. For example, patent application CN200910266661.8 or WO2006110783 discloses related methods for preparing 4-isobutyl-2-pyrrolidone; but these methods need to use hydrogen and/or high-pressure equipment or use other substrates to go through multiple steps to obtain, the reaction The time is long, the process is cumbersome and/or there are major unsafe factors. Therefore, there is a need for a method with low requirements on equipment, safety, simple operation process and high yield, so as to be suitable for industrial production.
发明内容Contents of the invention
本发明提供了一种制备普瑞巴林的方法,包括:将硝基化合物(01)转为内酰胺化合物4-异丁基-2-吡咯烷酮(02),再将化合物(02)水解、拆分,得到普瑞巴林(03),The invention provides a method for preparing pregabalin, comprising: converting a nitro compound (01) into a lactam compound 4-isobutyl-2-pyrrolidone (02), and then hydrolyzing and resolving the compound (02) , to obtain pregabalin (03),
其中,R为卤素、OR1或N R2R3;R1、R2和R3各自独立地为氢、(C1-C6)烷基、(C3-C6)环烷基、芳基、甲磺酰基、苯磺酰基或对甲苯磺酰基;其中,所述(C1-C6)烷基、(C3-C6)环烷基或芳基任选地未被取代或者被一个或多个取代基所取代;(C1-C6)烷基非限制性地包括甲基、乙基、异丙基、叔丁基等,(C3-C6)环烷基非限制性地包括环丙基、环己基;芳基非限制性地包括苯基、甲苯基,卤素是氟、氯、溴或碘;前述取代基非限制性地为卤素、三氟甲基、硝基、氰基、巯基、烷基硫基中的一个或多个。Wherein, R is halogen, OR 1 or N R 2 R 3 ; R 1 , R 2 and R 3 are each independently hydrogen, (C1-C6) alkyl, (C3-C6) cycloalkyl, aryl, methanesulfonate Acyl, benzenesulfonyl or p-toluenesulfonyl; wherein, the (C1-C6) alkyl, (C3-C6) cycloalkyl or aryl is optionally unsubstituted or substituted by one or more substituents ; (C1-C6) alkyl includes without limitation methyl, ethyl, isopropyl, tert-butyl, etc., (C3-C6) cycloalkyl includes without limitation cyclopropyl, cyclohexyl; aryl Non-limiting include phenyl, tolyl, halogen is fluorine, chlorine, bromine or iodine; the aforementioned substituents are non-limiting halogen, trifluoromethyl, nitro, cyano, mercapto, alkylthio one or more.
本发明提供了一种制备内酰胺化合物(02)的方法,所述方法不需要使用氢气(H2)和/或高压设备,通过简洁的反应步骤即可得到内酰胺化合物(02)。所述制备方法包括将式(01)所示的硝基化合物在金属卤化物存在下转化为式(02)所示的4-异丁基-2-吡咯烷酮,The present invention provides a method for preparing a lactam compound (02). The method does not require the use of hydrogen (H 2 ) and/or high-pressure equipment, and the lactam compound (02) can be obtained through simple reaction steps. The preparation method comprises converting the nitro compound shown in formula (01) into 4-isobutyl-2-pyrrolidone shown in formula (02) in the presence of a metal halide,
其中R如上述所定义。wherein R is as defined above.
硝基化合物(01)可以通过已知的方法制备得到,例如,李璟等人2007年在中国药物化学杂志第17卷第1期中报道的方法。The nitro compound (01) can be prepared by known methods, for example, the method reported by Li Jing et al. in Chinese Journal of Medicinal Chemistry, Vol. 17, No. 1 in 2007.
在一些实施方案中,从硝基化合物(01)制备得到内酰胺化合物(02)的方法包括:在金属卤化物存在下,硝基化合物(01)经过中间体(I-I)转化为内酰胺化合物(02),In some embodiments, the method for preparing the lactam compound (02) from the nitro compound (01) comprises: in the presence of a metal halide, the nitro compound (01) is converted into the lactam compound ( 02),
或者在一些实施方案中,硝基化合物(01)经过中间体(I-II)转化为内酰胺化合物(02),其中式(I-II)中R的定义同式(01),Or in some embodiments, the nitro compound (01) is converted into a lactam compound (02) through an intermediate (I-II), wherein the definition of R in the formula (I-II) is the same as that of the formula (01),
在硝基化合物(01)转化为内酰胺化合物(02)的过程中可以分离中间体(I-I)或(I-II),也可以不分离中间体。在一些实施方案中,不分离中间体。In the process of converting the nitro compound (01) to the lactam compound (02), the intermediate (I-I) or (I-II) may or may not be isolated. In some embodiments, intermediates are not isolated.
在一些实施方案中,硝基化合物(01)转化为内酰胺化合物(02)的过程中除了有金属卤化物存在,还使用了还原剂。In some embodiments, a reducing agent is used in addition to the metal halide during the conversion of the nitro compound (01) to the lactam compound (02).
在一些实施方案中,硝基化合物(01)转化为内酰胺化合物(02)的过程中除了有金属卤化物存在,还可以使用还原剂和金属催化剂。In some embodiments, in the process of converting the nitro compound (01) into the lactam compound (02), in addition to the presence of metal halides, reducing agents and metal catalysts can also be used.
在一些实施方案中,硝基化合物(01)在金属卤化物存在下,经过还原剂作用转化为内酰胺化合物(02);或者硝基化合物(01)经过金属催化剂和还原剂作用,然后在金属卤化物存在下,经还原剂作用转化为内酰胺化合物(02)。In some embodiments, the nitro compound (01) is converted into a lactam compound (02) through a reducing agent in the presence of a metal halide; or the nitro compound (01) is converted into a lactam compound (02) through a metal catalyst and a reducing In the presence of halides, it can be transformed into lactam compound (02) by reducing agent.
在一些实施方案中,所述金属卤化物为镍卤化物、铜卤化物、锡卤化物、钴卤化物、钯卤化物、或它们的水合物,或它们的任意组合。在另一些实施方案中,金属卤化物为镍卤化物、锡卤化物、或它们的水合物、或它们的任意组合。在一些实施方案中,所述镍卤化物为氯化镍(NiCl2)、二水合氯化镍(NiCl2·2H2O)、六水合氯化镍(NiCl2·6H2O)、溴化镍(NiBr2)、三水合溴化镍(NiBr2·3H2O)、或它们的任意组合;所述铜卤化物为碘化亚铜(CuI)、溴化亚铜(CuBr)、或它们的组合;所述锡卤化物为二水合氯化亚锡(SnCl2·2H2O),氯化亚锡(SnCl2),或它们的组合;所述钴卤化物为二氯化钴(CoCl2);所述钯卤化物为二氯化钯(PdCl2)。In some embodiments, the metal halide is nickel halide, copper halide, tin halide, cobalt halide, palladium halide, or hydrates thereof, or any combination thereof. In other embodiments, the metal halide is nickel halide, tin halide, or hydrates thereof, or any combination thereof. In some embodiments, the nickel halide is nickel chloride (NiCl 2 ), nickel chloride dihydrate (NiCl 2 ·2H 2 O), nickel chloride hexahydrate (NiCl 2 ·6H 2 O), bromide Nickel (NiBr 2 ), nickel bromide trihydrate (NiBr 2 ·3H 2 O), or any combination thereof; the copper halide is cuprous iodide (CuI), cuprous bromide (CuBr), or their The combination; the tin halide is stannous chloride dihydrate (SnCl 2 ·2H 2 O), stannous chloride (SnCl 2 ), or their combination; the cobalt halide is cobalt dichloride (CoCl 2 ); the palladium halide is palladium dichloride (PdCl 2 ).
在一些实施方案中,所述还原剂为甲酸或其盐、金属硼氢化物、金属氢化物、或它们的任意组合。在一些实施方案中,所述还原剂为甲酸铵、甲酸钠、甲酸、乙酸铵、硼氢化钾、硼氢化钠、四氢铝锂、氢化钠、二异丁基氢化铝、二甲氨基甲硼烷、或它们的任意组合。在一些实施方案中,所述还原剂为甲酸铵、硼氢化钾、硼氢化钠、或它们的任意组合。在一些实施方案中,所述还原剂为硼氢化钾、硼氢化钠、或它们的组合。In some embodiments, the reducing agent is formic acid or a salt thereof, a metal borohydride, a metal hydride, or any combination thereof. In some embodiments, the reducing agent is ammonium formate, sodium formate, formic acid, ammonium acetate, potassium borohydride, sodium borohydride, lithium aluminum hydride, sodium hydride, diisobutylaluminum hydride, dimethylaminoborane , or any combination of them. In some embodiments, the reducing agent is ammonium formate, potassium borohydride, sodium borohydride, or any combination thereof. In some embodiments, the reducing agent is potassium borohydride, sodium borohydride, or a combination thereof.
在一些实施方案中,所述金属催化剂为钯碳(Pd/C),氢氧化钯(Pd(OH)2),铂(Pt),铂碳(Pt/C),镍(Ni),或它们的任意组合。在另一些实施方案中,所述金属催化剂为钯碳(Pd/C)。在一些实施方案中,所述金属催化剂为镍(Ni)。In some embodiments, the metal catalyst is palladium on carbon (Pd/C), palladium hydroxide (Pd(OH) 2 ), platinum (Pt), platinum on carbon (Pt/C), nickel (Ni), or their any combination of . In other embodiments, the metal catalyst is palladium on carbon (Pd/C). In some embodiments, the metal catalyst is nickel (Ni).
硝基化合物(01)与所述金属卤化物的摩尔比为1:0.1到1:2.0。在一些实施方案中,所述摩尔比为1:0.3到1:1.0。在一些实施方案中,所述摩尔比为1:0.3到1:0.8。The molar ratio of the nitro compound (01) to the metal halide is 1:0.1 to 1:2.0. In some embodiments, the molar ratio is from 1:0.3 to 1:1.0. In some embodiments, the molar ratio is from 1:0.3 to 1:0.8.
硝基化合物(01)与所述还原剂的摩尔比为1:0.5到1:6。在一些实施方案中,所述摩尔比为1:1.0到1:6。在一些实施方案中,所述摩尔比为1:1.1到1:4.5。在一些实施方案中,所述摩尔比为1:1.3到1:4.5。在一些实施方案中,所述摩尔比为1:1.3到1:4。The molar ratio of the nitro compound (01) to the reducing agent is 1:0.5 to 1:6. In some embodiments, the molar ratio is from 1:1.0 to 1:6. In some embodiments, the molar ratio is from 1:1.1 to 1:4.5. In some embodiments, the molar ratio is from 1:1.3 to 1:4.5. In some embodiments, the molar ratio is from 1:1.3 to 1:4.
硝基化合物(01)与所述金属催化剂的重量比为1:0.01到1:0.2。在一些实施方案中,所述重量比为1:0.01到1:0.1。在一些实施方案中,所述重量比为1:0.01到1:0.05。The weight ratio of the nitro compound (01) to the metal catalyst is 1:0.01 to 1:0.2. In some embodiments, the weight ratio is from 1:0.01 to 1:0.1. In some embodiments, the weight ratio is 1:0.01 to 1:0.05.
在一些实施方案中,在反应结束后可以控制体系的pH值低于6,或者低于5,或者低于4.5,或者低于4,以消除过多的反应试剂。在一些实施方案中,通过盐酸水溶液调节,控制pH=2-3。在一些实施方案中,控制pH=1-2。In some embodiments, the pH value of the system can be controlled to be lower than 6, or lower than 5, or lower than 4.5, or lower than 4 after the reaction, so as to eliminate excess reagents. In some embodiments, pH=2-3 is controlled by adjusting with aqueous hydrochloric acid. In some embodiments, pH = 1-2 is controlled.
在硝基化合物(01)制备成内酰胺化合物(02)的过程中,反应溶剂为醇类溶剂、腈类溶剂、酮类溶剂、醚类溶剂、酯类溶剂、或它们的任意组合;所述醇类溶剂为甲醇、乙醇、异丙醇、或它们的任意组合;所述腈类溶剂为乙腈;所述酮类溶剂为丙酮;所述醚类溶剂为四氢呋喃、2-甲基四氢呋喃、甲基叔丁基醚或它们的任意组合;所述酯类溶剂为原甲酸三甲酯、原甲酸三乙酯或它们的组合。在一些实施方案中,反应溶剂为甲醇、乙醇、原甲酸三甲酯或它们的任意组合。During the preparation of the nitro compound (01) into the lactam compound (02), the reaction solvent is an alcohol solvent, a nitrile solvent, a ketone solvent, an ether solvent, an ester solvent, or any combination thereof; The alcohol solvent is methanol, ethanol, isopropanol, or any combination thereof; the nitrile solvent is acetonitrile; the ketone solvent is acetone; the ether solvent is tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether or any combination thereof; the ester solvent is trimethyl orthoformate, triethyl orthoformate or a combination thereof. In some embodiments, the reaction solvent is methanol, ethanol, trimethyl orthoformate, or any combination thereof.
在硝基化合物(01)制备成内酰胺化合物(02)的过程中,反应温度为-40℃到65℃。在一些实施方案中,反应温度为0℃到45℃。所述反应的反应时间为0.5小时到20小时。During the preparation of the nitro compound (01) into the lactam compound (02), the reaction temperature is -40°C to 65°C. In some embodiments, the reaction temperature is from 0°C to 45°C. The reaction time of the reaction is 0.5 hours to 20 hours.
在一些实施方案中,硝基化合物(01)制备成内酰胺化合物(02)的过程包括:在溶剂中,在NiCl2存在下,硝基化合物(01)和硼氢化钠反应得到内酰胺化合物(02)。In some embodiments, the process of preparing the nitro compound (01) into a lactam compound ( 02 ) comprises: in a solvent, in the presence of NiCl , reacting the nitro compound (01) with sodium borohydride to obtain the lactam compound ( 02).
在一些实施方案中,在溶剂中,在Pd/C存在下,硝基化合物(01)先与甲酸铵、硼氢化钾、硼氢化钠、或它们的任意组合反应,然后在NiCl2或SnCl2的存在下,与硼氢化钾或硼氢化钠反应制备成内酰胺化合物(02)。In some embodiments, the nitro compound (01) is first reacted with ammonium formate, potassium borohydride, sodium borohydride, or any combination thereof in the presence of Pd/C in a solvent, and then reacted in NiCl 2 or SnCl 2 In the presence of , react with potassium borohydride or sodium borohydride to prepare lactam compound (02).
在本发明的上下文中,无论是否使用“大约”或“约”等字眼,所有在此公开了的数字均为近似值。每一个数字的数值有可能会出现1%,2%,5%,7%,8%,10%,15%或20%等差异。每当公开一个具有N值的数字时,任何具有N+/-1%,N+/-2%,N+/-3%,N+/-5%,N+/-7%,N+/-8%,N+/-10%,N+/-15%或N+/-20%值的数字会被明确地公开,其中“+/-”是指加或减。每当公开一个数值范围中的一个下限,AL,和一个上限,AU,时,任何处于该公开了的范围之内的数值会被明确地公开。特别是,包含了该范围内的以下数值:A=AL+k*(AU-AL),其中k是一个按1%的增量增加的从1%到100%的变量。如:1%,2%,3%,4%,5%...50%,51%,52%...95%,96%,97%,98%,99%或100%。另外,还特别包含了在此公开了的上述以两个A数字定义的数值范围。In the context of the present invention, all numbers disclosed herein are approximations, whether or not the word "about" or "approximately" is used. The value of each figure may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15% or 20%. Whenever a number with a value of N is disclosed, any number with N+/-1%, N+/-2%, N+/-3%, N+/-5%, N+/-7%, N+/-8%, N+ Figures for /-10%, N+/-15% or N+/-20% values are explicitly disclosed, where "+/-" means plus or minus. Whenever a lower limit, AL, and an upper limit, AU, of a numerical range are disclosed, any numerical value within that disclosed range is expressly disclosed. In particular, the following values are included in the range: A=AL+k*(AU-AL), where k is a variable from 1% to 100% in increments of 1%. Such as: 1%, 2%, 3%, 4%, 5%...50%, 51%, 52%...95%, 96%, 97%, 98%, 99% or 100%. In addition, the above-mentioned numerical ranges defined by two A numbers disclosed herein are also specifically included.
具体实施方式Detailed ways
为了进一步理解本发明,下面结合实施例对本发明进行详细说明。In order to further understand the present invention, the present invention will be described in detail below in conjunction with examples.
以下实施例中,R为乙氧基。若R为其它基团,请参照以下实施例来制备内酰胺化合物(02)。In the following examples, R is ethoxy. If R is other groups, please refer to the following examples to prepare lactam compound (02).
实施例1Example 1
在600毫升甲醇中,加入50.00克硝基化合物(01),18.04克NiCl2·6H2O;将溶液降温至0℃-5℃,加入硼氢化钠18.2克。加毕,升温至40℃-45℃搅拌12小时。然后将混合液降温至室温,滴入盐酸水溶液,调节pH=2-3。将反应液减压浓缩至体系无明显甲醇(气相色谱检测),加入乙酸乙酯萃取,水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物31.20克,收率96.0%,纯度99.10%。质谱:m/z=142[M+1],m/z=283[2M+1];核磁氢谱:(CDCl3,400MHz)0.91(m,6H),1.33(m,2H),1.61(m,1H),1.99(m,1H),2.17(m,1H),2.44(m,1H),3.01(m,1H),3.50(m,1H),6.71(br,1H)。In 600 ml of methanol, add 50.00 g of nitro compound (01), 18.04 g of NiCl 2 ·6H 2 O; cool the solution to 0°C-5°C, and add 18.2 g of sodium borohydride. After the addition, the temperature was raised to 40°C-45°C and stirred for 12 hours. Then the mixture was cooled to room temperature, and aqueous hydrochloric acid was added dropwise to adjust the pH to 2-3. The reaction solution was concentrated under reduced pressure until no obvious methanol was found in the system (detected by gas chromatography), ethyl acetate was added for extraction, washed with water, the organic layer was dried and concentrated to obtain lactam compound (02), 31.20 g of light yellow oil, yield 96.0% , 99.10% purity. Mass Spectrum: m/z=142[M+1], m/z=283[2M+1]; NMR Proton Spectrum: (CDCl 3 ,400MHz)0.91(m,6H),1.33(m,2H),1.61( m,1H), 1.99(m,1H), 2.17(m,1H), 2.44(m,1H), 3.01(m,1H), 3.50(m,1H), 6.71(br,1H).
实施例2Example 2
50.00克硝基化合物(01)溶于600毫升甲醇溶液,降温至-15℃;加入22.05克硼氢化钾,10.93克NiCl2·6H2O;加毕,升温至45℃,搅拌12小时。然后将混合液降温至0℃-5℃,加入盐酸溶液调节pH=2-3。将混合液减压浓缩,乙酸乙酯萃取,水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物32.00克,收率98.5%,纯度96.50%;质谱:m/z=142[M+1],m/z=283[2M+1]。50.00 g of nitro compound (01) was dissolved in 600 ml of methanol solution, cooled to -15°C; 22.05 g of potassium borohydride and 10.93 g of NiCl 2 ·6H 2 O were added; after addition, the temperature was raised to 45°C and stirred for 12 hours. Then the mixture was cooled to 0°C-5°C, and hydrochloric acid solution was added to adjust the pH to 2-3. The mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with water, and the organic layer was dried and concentrated to obtain lactam compound (02), 32.00 g of light yellow oil, yield 98.5%, purity 96.50%; mass spectrum: m/z= 142[M+1], m/z=283[2M+1].
实施例3Example 3
500毫升的甲醇中,加入50.00克硝基化合物(01),31.35克NiBr2·3H2O;降温至-5℃,加入27.50克的氢化钠。加毕,升温至40℃-45℃搅拌10小时。然后将反应混合液降温至0℃-5℃,加入盐酸水溶液调节pH=2-3。将混合液减压浓缩,加入乙酸乙酯萃取,水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物31.10克,收率95.7%,纯度99.11%;质谱:m/z=142[M+1],m/z=283[2M+1]。To 500 ml of methanol, add 50.00 g of nitro compound (01), 31.35 g of NiBr 2 ·3H 2 O; cool down to -5°C, and add 27.50 g of sodium hydride. After the addition, the temperature was raised to 40°C-45°C and stirred for 10 hours. Then the temperature of the reaction mixture was lowered to 0°C-5°C, and aqueous hydrochloric acid was added to adjust the pH=2-3. The mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with water, and the organic layer was dried and concentrated to give lactam compound (02), 31.10 g of light yellow oil, yield 95.7%, purity 99.11%; mass spectrum: m/z =142[M+1], m/z=283[2M+1].
实施例4Example 4
900毫升甲醇中,加入50.00克硝基化合物(01),24.65克NiCl2·6H2O;降温至0℃-5℃,加入18.20克硼氢化钠。加毕,升温至40℃-45℃,搅拌10小时。然后将反应混合液降温至5℃-25℃,加入盐酸水溶液调节pH=2-3。将反应混合液减压浓缩,加入乙酸乙酯萃取,水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物31.22克,收率96.0%,纯度99.10%;质谱:m/z=142[M+1],m/z=283[2M+1]。To 900 ml of methanol, add 50.00 g of nitro compound (01), 24.65 g of NiCl 2 ·6H 2 O; cool down to 0°C-5°C, and add 18.20 g of sodium borohydride. After the addition, the temperature was raised to 40°C-45°C and stirred for 10 hours. Then the temperature of the reaction mixture was lowered to 5°C-25°C, and aqueous hydrochloric acid was added to adjust the pH to 2-3. The reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with water, and the organic layer was dried and concentrated to give lactam compound (02), 31.22 g of light yellow oil, yield 96.0%, purity 99.10%; mass spectrum: m/ z=142[M+1], m/z=283[2M+1].
实施例5Example 5
600毫升甲醇中,加入50.00克硝基化合物(01),5.20克SnCl2·2H2O;降温至0℃-5℃,加入18.20克的硼氢化钠。加毕,将反应混合液升温至40℃-45℃,搅拌10小时。然后将反应混合液降温至5℃-15℃,加入盐酸水溶液调节pH=2-3。然后将反应混合液减压浓缩,加入乙酸乙酯萃取,饱和食盐水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物31.30克,收率96.4%,纯度99.10%;质谱:m/z=142[M+1],m/z=283[2M+1]。50.00 g of nitro compound (01), 5.20 g of SnCl 2 ·2H 2 O were added to 600 ml of methanol; the temperature was lowered to 0°C-5°C, and 18.20 g of sodium borohydride was added. After the addition was complete, the temperature of the reaction mixture was raised to 40°C-45°C and stirred for 10 hours. Then the temperature of the reaction mixture was lowered to 5°C-15°C, and aqueous hydrochloric acid was added to adjust the pH to 2-3. Then the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated brine, and the organic layer was dried and concentrated to obtain lactam compound (02), 31.30 g of light yellow oil, yield 96.4%, purity 99.10%; mass spectrometry : m/z=142[M+1], m/z=283[2M+1].
实施例6Example 6
50毫升乙醇中,加入5克硝基化合物(01),6.50克甲酸铵和5%的Pd/C 0.25克,室温搅拌6.5小时;过滤,将滤液浓缩,乙酸乙酯萃取,有机层水洗涤、干燥后浓缩得黄色油状物3.30克。将此黄色油状物溶于40毫升甲醇中,冷却到-10℃,加入2.51克硼氢化钾和1.37克NiCl2·6H2O,然后升温至45℃搅拌12小时。将混合液降温至-5℃-0℃,滴入盐酸水溶液调节pH=1-2;混合液减压浓缩至气相检测无甲醇,加入乙酸乙酯萃取,水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物2.71克,纯度99.12%,收率82.6%;质谱:m/z=142[M+1],m/z=283[2M+1]。In 50 milliliters of ethanol, add 5 grams of nitro compound (01), 6.50 grams of ammonium formate and 0.25 grams of 5% Pd/C, stir at room temperature for 6.5 hours; filter, concentrate the filtrate, extract with ethyl acetate, wash the organic layer with water, After drying and concentrating, 3.30 g of a yellow oily substance was obtained. The yellow oil was dissolved in 40 ml of methanol, cooled to -10°C, 2.51 g of potassium borohydride and 1.37 g of NiCl 2 ·6H 2 O were added, then heated to 45°C and stirred for 12 hours. Cool the mixed solution to -5°C-0°C, add hydrochloric acid aqueous solution dropwise to adjust pH = 1-2; concentrate the mixed solution under reduced pressure until no methanol is detected in the gas phase, add ethyl acetate for extraction, wash with water, dry the organic layer and concentrate to obtain Amide compound (02), light yellow oil 2.71g, purity 99.12%, yield 82.6%; mass spectrum: m/z=142[M+1], m/z=283[2M+1].
实施例7Example 7
60毫升甲醇中,加入5克硝基化合物(01),6.50克甲酸铵和10%的Pd/C 0.15克,室温搅拌6.5小时;然后将反应混合液降温至0℃,加入硼氢化钠1.09克和3.01克NiCl2·6H2O,加完后升温至45℃搅拌12小时。然后将反应混合液降温至0℃-5℃,滴入盐酸水溶液调节pH=1-2。然后将反应混合液减压浓缩至无明显甲醇,加入乙酸乙酯萃取,饱和食盐水洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物3.05克;收率94%,纯度99.10%;质谱:m/z=142[M+1],m/z=283[2M+1]。In 60 ml of methanol, add 5 g of nitro compound (01), 6.50 g of ammonium formate and 0.15 g of 10% Pd/C, stir at room temperature for 6.5 hours; then cool the reaction mixture to 0°C, add 1.09 g of sodium borohydride and 3.01 g of NiCl 2 ·6H 2 O, after the addition, the temperature was raised to 45°C and stirred for 12 hours. Then the temperature of the reaction mixture was lowered to 0°C-5°C, and aqueous hydrochloric acid was added dropwise to adjust the pH to 1-2. Then the reaction mixture was concentrated under reduced pressure until there was no obvious methanol, extracted with ethyl acetate, washed with saturated brine, dried and concentrated to give lactam compound (02), 3.05 g of light yellow oil; yield 94%, purity 99.10%; Mass spectrum: m/z = 142 [M+1], m/z = 283 [2M+1].
实施例8Example 8
60毫升甲醇中,加入5克硝基化合物(01),6.50克甲酸铵和5%的Pd/C 0.25克,室温搅拌6.5小时;然后将反应混合液降温至0℃,加入1.84克硼氢化钠和4.93克SnCl2·2H2O。将反应混合液升温至45℃,搅拌12小时。然后将反应混合液降温至0℃-5℃,加盐酸水溶液调节pH=1-2。然后将反应混合液减压浓缩至无明显甲醇,加入乙酸乙酯萃取,饱和NaCl溶液洗涤,有机层干燥后浓缩得内酰胺化合物(02),淡黄色油状物3.04克;收率93.6%,纯度99.20%;质谱:m/z=142[M+1],m/z=283[2M+1]。In 60 milliliters of methanol, add 5 grams of nitro compound (01), 6.50 grams of ammonium formate and 0.25 grams of 5% Pd/C, stir at room temperature for 6.5 hours; then cool the reaction mixture to 0°C, add 1.84 grams of sodium borohydride and 4.93 grams of SnCl 2 ·2H 2 O. The reaction mixture was warmed to 45°C and stirred for 12 hours. Then the temperature of the reaction mixture was lowered to 0°C-5°C, and aqueous hydrochloric acid was added to adjust the pH to 1-2. Then the reaction mixture was concentrated under reduced pressure until there was no obvious methanol, extracted with ethyl acetate, washed with saturated NaCl solution, and the organic layer was dried and concentrated to give lactam compound (02), 3.04 g of light yellow oil; yield 93.6%, purity 99.20%; mass spectrum: m/z = 142 [M+1], m/z = 283 [2M+1].
以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也落入本发明权利要求的保护范围内。The descriptions of the above embodiments are only used to help understand the method and core idea of the present invention. It should be pointed out that for those skilled in the art, without departing from the principle of the present invention, some improvements and modifications can be made to the present invention, and these improvements and modifications also fall within the protection scope of the claims of the present invention.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380033724.XA CN104395286A (en) | 2012-07-02 | 2013-06-28 | A kind of preparation method of lactam compound |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102226037 | 2012-07-02 | ||
CN201210222603 | 2012-07-02 | ||
CN201310117058X | 2013-04-04 | ||
CN201310117058 | 2013-04-04 | ||
PCT/CN2013/078258 WO2014005494A1 (en) | 2012-07-02 | 2013-06-28 | Method of preparing lactam compound |
CN201380033724.XA CN104395286A (en) | 2012-07-02 | 2013-06-28 | A kind of preparation method of lactam compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104395286A true CN104395286A (en) | 2015-03-04 |
Family
ID=49881328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380033724.XA Pending CN104395286A (en) | 2012-07-02 | 2013-06-28 | A kind of preparation method of lactam compound |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104395286A (en) |
WO (1) | WO2014005494A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641093A (en) * | 2016-07-20 | 2018-01-30 | 江西科维协同创新药物有限公司 | The method that one kind prepares the pyrrolidones of 4 (S) isobutyl group 2 |
CN115475162A (en) * | 2022-10-18 | 2022-12-16 | 浙江震元制药有限公司 | Application of 4-isobutyl-2-pyrrolidone in preparation of analgesic and analgesic drug |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1642899A (en) * | 2002-01-25 | 2005-07-20 | 格吕伦塔尔有限公司 | Methods for producing substituted acrylic acid esters and use of the latter for producing substituted dollar G(G)-amino acids |
CN101300224A (en) * | 2005-04-11 | 2008-11-05 | 特瓦制药工业有限公司 | Process for making (s)-pregabalin |
-
2013
- 2013-06-28 CN CN201380033724.XA patent/CN104395286A/en active Pending
- 2013-06-28 WO PCT/CN2013/078258 patent/WO2014005494A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1642899A (en) * | 2002-01-25 | 2005-07-20 | 格吕伦塔尔有限公司 | Methods for producing substituted acrylic acid esters and use of the latter for producing substituted dollar G(G)-amino acids |
CN101300224A (en) * | 2005-04-11 | 2008-11-05 | 特瓦制药工业有限公司 | Process for making (s)-pregabalin |
Non-Patent Citations (2)
Title |
---|
E. J. COREY等: ""Enantioselective Michael Addition of Nitromethane to r,â-Enones Catalyzed by Chiral Quaternary Ammonium Salts.A Simple Synthesis of (R)-Baclofen"", 《ORG. LETT.》 * |
E. J. COREY等: ""Enantioselective Michael Addition of Nitromethane to r,â-Enones Catalyzed by Chiral Quaternary Ammonium Salts.A Simple Synthesis of (R)-Baclofen"", 《ORG. LETT.》, vol. 2, no. 26, 23 November 2000 (2000-11-23), pages 4257 - 4259 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641093A (en) * | 2016-07-20 | 2018-01-30 | 江西科维协同创新药物有限公司 | The method that one kind prepares the pyrrolidones of 4 (S) isobutyl group 2 |
CN115475162A (en) * | 2022-10-18 | 2022-12-16 | 浙江震元制药有限公司 | Application of 4-isobutyl-2-pyrrolidone in preparation of analgesic and analgesic drug |
Also Published As
Publication number | Publication date |
---|---|
WO2014005494A1 (en) | 2014-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110590557A (en) | A kind of nitration method of aryl phenols or aryl ether derivatives | |
CN104326923B (en) | A kind of synthetic method of succsinic acid desmethylvenlafaxine | |
CN104945294B (en) | Compound containing trifluoromethylthio and preparation method thereof | |
CN104395286A (en) | A kind of preparation method of lactam compound | |
CN104387252B (en) | A kind of synthetic method of aryl ketones compounds | |
CN104496909B (en) | A kind of double-core benzimidazole ion salt and its preparation method and application | |
WO2020177347A1 (en) | Oxygen-guided synthesis method for 7-alkynyl indole compound | |
CN116655529A (en) | Method for synthesizing 3-aryl quinoline compound by nickel catalysis | |
CN112645871B (en) | Synthetic method of N-CF2H-1,2-dihydropyridin-2-one compound | |
CN106349082B (en) | A kind of preparation method of meta alkyl benzene amine | |
CN111747975B (en) | Preparation method of bedaquiline racemate and intermediate thereof | |
CN104072360A (en) | Synthetic method for natural cinnamic acid | |
CN115819356A (en) | A kind of method for preparing tetrahydroquinoxaline compound | |
EP3782977A1 (en) | Cyclopropanation method and reagent | |
CN101265201B (en) | A kind of synthetic method of tramadol hydrochloride | |
CN112694427A (en) | Method for preparing 2, 3-dimethyl sulfide | |
CN113493385B (en) | Method for synthesizing butenafine hydrochloride | |
CN102863493B (en) | Preparation method of beta-thymidine | |
CN109912661A (en) | Pyrimidine-pyrazole metal ruthenium complex with catalytic performance and preparation method thereof | |
CN113493388B (en) | Synthesis method of butenafine hydrochloride | |
CN114656389B (en) | A kind of synthetic method of 1-phenylpyrrolidine | |
RU2522460C1 (en) | Method of producing alkenyl anthraquinones | |
CN102731386A (en) | Preparation method of para-diimide derivative | |
CN110938086B (en) | Half-sandwich ruthenium-thione complex and preparation method thereof, ammonia borane hydrolysis method and nitrobenzene compound reduction method | |
CN110511147B (en) | A kind of reduction method of nitroalkene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150304 |